Orexin agonists move from narcolepsy treatment to broader brain therapy ambitions
US approval of Orzeyful (oveporexton) in August has done more than add a new therapy for narcolepsy. It has pushed a once-niche neuropeptide pathway into the center of drug development, with researchers now asking whether orexin biology can be translated into treatments for disorders that extend well beyond sleep medicine.
The enthusiasm comes from a simple but powerful concept: orexins do not merely suppress sleepiness. They help stabilize wakefulness itself. When that system fails, the result is not just fatigue but the abrupt fragmentation of alertness that defines narcolepsy type 1, including cataplexy, daytime sleep attacks and the inability to maintain a coherent sleep–wake rhythm.
That biology has made orexin agonists unusually attractive. Unlike older therapies that mainly manage symptoms, these compounds aim at the root defect in a disorder linked to the loss of a small population of hypothalamic neurons. The therapeutic logic is unusually direct: replace the signal, restore the state.
From a hypothalamic peptide to a druggable target
The scientific path began in the mid-1990s, when Luis de Lecea and colleagues at the Scripps Research Institute were searching for proteins produced in specific regions of the brain. Working in the hypothalamus, they identified two neuropeptides they named hypocretin 1 and 2. Around the same time, researchers in Texas isolated the equivalent peptides in rats and called them orexin A and B.
Those parallel discoveries turned out to be foundational. Takeshi Sakurai, then working in the laboratory of Masashi Yanagisawa at the University of Texas Southwestern Medical Center, helped identify the orexins and initially suspected they were involved in feeding behavior. The name itself reflects that early hypothesis, derived from the Greek orexis, meaning appetite.
The experimental turn came when the team blocked orexin signaling in animals. The animals sometimes abruptly collapsed. In a neurobiological sense, the collapse was revealing: it resembled cataplexy, the sudden loss of muscle tone that is a hallmark of narcolepsy type 1 in humans. Orexin was not simply a wakefulness trigger. It was a stabilizer, preventing the brain from slipping out of alertness.
That insight changed the field.
A small neuronal loss with a large clinical footprint
Subsequent work sharpened the clinical relevance of the pathway. Emmanuel Mignot and colleagues at Stanford identified a mutation in the gene encoding orexin receptor 2 as the cause of canine narcolepsy. Jerome Siegel and collaborators at the University of California, Los Angeles, later found that people who died with narcolepsy type 1 almost always had a profound loss of the neurons that produce orexins.
The scale of the neuronal loss is striking. Only about 70,000 orexin-producing cells are involved among the hundreds of thousands in the hypothalamus, yet their absence is enough to dismantle wakefulness stability. In a bedside setting, that explains why narcolepsy can be so disruptive despite the apparently small anatomical footprint of the lesion. A tiny cluster of cells exerts an outsized effect on daytime functioning, vigilance and social safety.
For patients, the consequence is immediate and concrete. When those neurons disappear, the brain cannot find an effective workaround. Other arousal systems can compensate only partially, which is why symptoms persist and why the disorder has remained so difficult to treat with conventional stimulants and sedating nighttime regimens.
Takeda’s first human program started with a single molecular hit
Takeda’s entry into the field began as a side project in the late 2000s. A technician at the company had a friend with narcolepsy type 1 and began searching for a molecule that could bind orexin receptors and normalize the sleep–wake cycle. When the company screened its libraries, only one candidate emerged: TAK-925.
The decision to pursue it carried obvious risk. A single hit is not a comfortable starting point for a drug-discovery program. Still, the compound performed well in animals, and the first human trial launched in 2017. The personal connection to the disease remained close: the technician even drove his friend to the study center, and the response was strong enough that he phoned the company leadership immediately.
That kind of anecdote is not a substitute for trial evidence, but it fits the biology. An orexin agonist should work quickly if it is successfully engaging the target, because it is not rebuilding neurons or rewiring circuits. It is restoring a missing signal. In practice, that can translate into a more immediate sense of being awake rather than merely less sleepy.
Mignot, who led Takeda’s late-stage trials, says people report that after taking the drug, they suddenly know what it is to be awake. The phrasing captures the core clinical promise of the class: a treatment that restores an experience patients have lost.
Why drug developers are eyeing attention, alertness and beyond
With Orzeyful now approved in three countries, commercial interest is rapidly expanding. Analysts estimate the global market for narcolepsy drugs could exceed US$6.4 billion by 2031, and competitors are moving quickly to claim a share of it. That momentum reflects not only the prevalence of narcolepsy, which affects roughly three million people worldwide, but also the likelihood that many cases remain unrecognized or mislabeled.
The more ambitious question is what comes next. Researchers are already exploring orexin agonists in ADHD and other disorders in which attention and alertness are dysregulated. The rationale is plausible, because orexin sits upstream of systems that regulate arousal, motivation, metabolism, mood, appetite and memory. In disorders where vigilance is unstable, a drug that stabilizes wakefulness could have effects that extend beyond sleep.
Still, the leap from narcolepsy to broader neuropsychiatric use should not be treated as automatic. Narcolepsy type 1 is a disorder of orexin deficiency, which makes it an unusually clean target. Other conditions will almost certainly be more heterogeneous, and the magnitude of benefit may depend on whether orexin signaling is actually part of the disease biology rather than merely adjacent to it.
A pathway with blockbuster expectations and unresolved boundaries
The comparison to GLP-1 drugs is hard to ignore. Like those agents, orexin agonists may begin in one indication and then expand if the underlying biology proves useful across several disorders. The difference is that the orexin story has so far been anchored in the central nervous system, where the link between mechanism and behavior is visible in real time through sleep, cataplexy and daytime function.
What remains uncertain is not whether orexin matters, but how far its therapeutic reach extends. Narcolepsy offers the strongest proof of principle because the disease mechanism is so direct. Broader indications will need careful clinical testing, especially if developers hope to move from symptom control to genuine disease modification in conditions beyond sleep medicine.
For now, the field is defined by a rare convergence of neuroscience and pharmacology: a known circuit, a missing signal and a drug class designed to replace it. The next readouts will determine whether orexin agonists stay a narcolepsy breakthrough or become a wider platform for treating disorders of alertness.